Compare · ABSI vs OABI
ABSI vs OABI
Side-by-side comparison of Absci Corporation (ABSI) and OmniAb Inc. (OABI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and OABI operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- ABSI is the larger of the two at $1.50B, about 2.3x OABI ($661.5M).
- Over the past year, ABSI is up 71.1% and OABI is up 169.4% - OABI leads by 98.3 points.
- ABSI has been more active in the news (6 items in the past 4 weeks vs 2 for OABI).
- ABSI has more recent analyst coverage (21 ratings vs 5 for OABI).
PerformanceABSI+71.09%OABI+169.41%
2025-10-16+0.00%2026-10-16
- Company
- Absci Corporation
- OmniAb Inc.
- Price
- -
- -
- Market cap
- $1.50B
- $661.5M
- 1M return
- -10.16%
- +3.27%
- 1Y return
- +71.09%
- +169.41%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2021
- News (4w)
- 6
- 2
- Recent ratings
- 21
- 5
ABSI
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Latest ABSI
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- CFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,320 shares, decreasing direct ownership by 2% to 483,144 units (SEC Form 4) (withholding obligation)
- Absci to Participate in Upcoming Investor Conferences
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- SEC Form 10-Q filed by Absci Corporation
Latest OABI
- OmniAb to Report Third Quarter 2026 Financial Results on October 30
- OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
- OmniAb to Host Investor & Analyst Day on October 6, 2026
- OmniAb to Participate in Upcoming Investor Conferences
- OmniAb Raises 2026 Financial Guidance
- OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
- SEC Form 10-Q filed by OmniAb Inc.
- OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
- SEC Form 4 filed by Chief Operating Officer Nwachuku Amechi Ekeke